Colmar, France

Catherine Cannet

This inventor holds 1 USPTO granted patent. Top assignee: Laboratoires Pos. Active years: 1988.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1988

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Catherine Cannet

Introduction

Catherine Cannet is a notable inventor based in Colmar, France. She has made significant contributions to the field of medicine, particularly in the treatment of glaucoma. Her innovative work has led to the development of a unique compound that has the potential to improve patient outcomes.

Latest Patents

Catherine Cannet holds 1 patent for her invention titled "Ethers and oxime ethers of alkylamino alcohols as medicaments." This patent describes a method for treating glaucoma through the application of a physiologically active compound to the eye. The compound is characterized by a specific formula, where each of R₃ and R₄ can be selected from hydrogen, alkyl, alkenyl, and cycloalkyl radicals, or can form a cycloalkylidene radical.

Career Highlights

Throughout her career, Catherine has demonstrated a strong commitment to advancing medical science. Her work at Laboratoires Pos has been instrumental in developing new therapeutic options for patients suffering from glaucoma. Her innovative approach and dedication to research have positioned her as a key figure in her field.

Collaborations

Catherine has collaborated with esteemed colleagues such as Mohammed Bouzoubaa and Jacques Himber. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the development of new medical solutions.

Conclusion

Catherine Cannet's contributions to the field of medicine, particularly in glaucoma treatment, highlight her innovative spirit and dedication to improving patient care. Her work continues to inspire future advancements in medical research and therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…